Might just be some value being attributed to yesterday's RNS or the one before that where multi billion dollar Bruker wanted to have a go on little old Avacta's test?
Yet more evidence that Affimers will replace antibodies in cutting edge tech, who owns the IP for Affimers?
"We look forward to launching new class of MSC therapies that overcome the limitations of existing antibodies and cells and provide meaningful treatment options to patients suffering from refractory diseases."